Who makes Xomolix 1.25 mg?

Xomolix 1.25 mg is developed by Medical University of Gdansk.

What development phase is Xomolix 1.25 mg in?

Xomolix 1.25 mg is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Xomolix 1.25 mg

Medical University of Gdansk · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Xomolix 1.25 mg
Sponsor	Medical University of Gdansk
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Gender Influence on Torsadogenic Actions of Droperidol. (NA)
Droperidol and Cardiac Repolarization (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Xomolix 1.25 mg CI brief — competitive landscape report
Xomolix 1.25 mg updates RSS · CI watch RSS
Medical University of Gdansk portfolio CI